scholarly journals Fibroblast growth factor 21 (FGF21) is a sensitive marker of osteoporosis in haemodialysis patients: a cross-sectional observational study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Lili Zhu ◽  
Min Li ◽  
Qianqian Zha ◽  
Min Yang ◽  
Jirong Yu ◽  
...  
Keyword(s):  
Renal Function ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Residual Renal Function ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Mineral And Bone Disorder ◽  
Cross Sectional ◽  
Ct Attenuation ◽  
Attenuation Values

Abstract Introduction Osteoporosis is one of the important bone abnormalities in chronic kidney disease-mineral and bone disorder (CKD-MBD) and still lacks a sensitive biomarker to diagnose. Fibroblast growth factor 21 (FGF21) can stimulate bone loss in patients with diabetes and increase in CKD patients. In this study, we investigated whether FGF21 could serve as a biomarker to predict osteoporosis in a haemodialysis cohort. Methods We recorded demographic information, biochemical data, and serum FGF21 and FGF23 levels and measured the CT attenuation values of 339 haemodialysis patients from two large medical centres. We assessed the correlation of CT attenuation values with serum FGF21 and FGF23 levels and tested whether they were independent factors for osteoporosis. ROC curves were constructed to compare the prognostic value of FGF21 and FGF23 for osteoporosis. Results Based on the CT attenuation value, serum FGF21 levels were higher in our osteoporosis group (median 640.86 pg/ml vs. 245.46 pg/ml, P ˂ 0.01). Meanwhile, FGF21 (r = -0.136, P < 0.05) and FGF23 (r = -0.151, P < 0.05) were both negatively associated with osteoporosis. Moreover, FGF21 (β = -0.067, P < 0.05) was an independent factor for osteoporosis. Furthermore, FGF21 combined with age yielded a marked specificity (90.5 %) and sensitivity (61.8 %) in predicting osteoporosis of haemodialysis patients with less residual renal function. Conclusions FGF21 has a positive relationship with the incidence of osteoporosis in patients on haemodialysis. FGF21 combined with age is a good predictive biomarker for osteoporosis in patients on haemodialysis, especially those with less residual renal function.

scholarly journals Fibroblast Growth Factor 21 (FGF21), Free Fatty Acid (FFA), High Sensitivity C-reactive Protein (hsCRP) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Among Indonesian Obese Non-Diabetic Males

2009 ◽  
Vol 1 (3) ◽  
pp. 76 ◽  
Author(s):  
Yani Lina ◽  
Gatot Susilo Lawrence ◽  
Andi Wijaya ◽  
Suryani As'ad
Keyword(s):  
Blood Pressure ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
High Sensitivity ◽  
Significant Negative Correlation ◽  
Fibroblast Growth Factor 21 ◽  
Compensatory Mechanism ◽  
Model Assessment ◽  
Fibroblast Growth ◽  
Cross Sectional

BACKGROUND: Fibroblast growth factor-21 (FGF21) is known as an important endocrine and paracrine regulator of metabolic homeostasis. Recent studies have shown that FGF21 attenuates lipolysis in human adipocytes, which is suggested as a FGF21's mechanism as anti-hyperlipidemia, anti-hyperglycemia and anti-obesity. The aim of this study was to measure the correlation between FGF21, FFA, hsCRP and HOMA-IR among Indonesian obese non diabetic males.METHOD: The study was observational with cross sectional design. The analysis was done in 137 subjects aged 30-60 years with non diabetic abdominal obesity. We measured the biochemical markers FGF21, FFA, hsCRP, fasting insulin and fasting glucose. We also measured weight, height, waist circumrefence (WC), creatinine, serum glutamin oxaloacetic transaminase (SGOT), and serum glutamic pyruvic transaminase (SGPT), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Correlation between markers was measured using Pearson and Spearman's analysis.  RESULT: There were significant positive correlations between FGF21-HOMA-IR (r=0.314, p=0.000); FGF21-WC (r=0.173, p=0.043); FFA=hsCRP (r=0.270, p=0.001); and WC-HOMA-IR (r=0.279, p=0.001). There was significant negative correlation between FGF21-FFA (r=-0.038, p=0.657) and FGF21-hsCRP (r=-0.061, p=0.482). CONCLUSION: In this study we found that although there was no significant correlation, FGF21 might act as an anti-lipolytic and anti-inflammation agent among Indonesian obese non-diabetic males. Our findings agree with results of previous studies that the positive correlation between FGF21-WC and FGF21-HOMA-IR moght occur as a compensatory mechanism or resistance to FGF21 in obesity.KEYWORDS: Obesity, FGF21, FFA, hsCRP, HOMA-IR

scholarly journals Serum Fibroblast Growth Factor 21 in Patients with and without Pterygia

2020 ◽  
Author(s):  
Ghalam-Hosein Yaghoobi ◽  
Saeed Shokoohi-Rad ◽  
Hamid Jafarzadeh ◽  
Elham Abodollahi
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Cross Sectional Study ◽  
Fibroblast Growth Factor 21 ◽  
Enzyme Linked Immunosorbent Assay ◽  
Fibroblast Growth ◽  
Chi Square ◽  
Cross Sectional ◽  
Liver And Kidney ◽  
History Of

Purpose: Pterygium is a common fibro-vascular-related eye disease. The fibroblast growth factor 21 (FGF21) helps reduce neovascularization. Previous studies have shown that the serum level of FGF21 correlates with vascular eye diseases such as diabetic retinopathy and retinopathy of prematurity. In this study, the serum FGF21 is compared in patients with and without pterygium. Methods: This descriptive-analytical cross-sectional study examines individuals with pterygium who visited the Ophthalmology Clinic of Khatam-al-Anbia Hospital in Mashhad, Iran, during 2017–2018. Control subjects were selected from healthy people without pterygium disease. Patients with a history of acute illness, chronic liver and kidney disease, diabetes, cancer, malnutrition and drug use, women who were pregnant or breastfeeding, and subjects who were taking anticonvulsants or glucocorticoids were excluded as these may affect insulin and glycosuria levels. Sixty people (30 in each group) were chosen using the convenient sampling method. Intravenous blood samples were taken from all patients. After preparing the patients, the freeze was checked using the enzyme-linked immunosorbent assay (ELISA) method after samples had been taken. Data were analyzed by SPSS using an independent t-test, Mann–Whitney, Chi-square, Kruskal–Wallis, and Kolmogorov–Smirnov tests (

Relationship Between Residual Renal Function and Serum Fibroblast Growth Factor 23 in Patients on Peritoneal Dialysis

2014 ◽  
Vol 18 (5) ◽  
pp. 383-390 ◽  
Author(s):  
Shunsuke Yamada ◽  
Kazuhiko Tsuruya ◽  
Masatomo Taniguchi ◽  
Hisako Yoshida ◽  
Masanori Tokumoto ◽  
...  
Keyword(s):  
Renal Function ◽  
Peritoneal Dialysis ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Residual Renal Function ◽  
Fibroblast Growth

scholarly journals Fibroblast Growth Factor 21 Predicts and Promotes Vascular Calcification in Haemodialysis Patients

2021 ◽  
pp. 1-14
Author(s):  
Liqiong Jiang ◽  
Qing Yin ◽  
Min Yang ◽  
Min Li ◽  
Mingming Pan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Thoracic Aorta ◽  
Vascular Calcification ◽  
Calcium Deposition ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Mineral Density ◽  
Cross Sectional ◽  
Mesenchymal Transition

<b><i>Background:</i></b> Cardiovascular disease (CVD) is the leading cause of death in haemodialysis (HD) patients. Vascular calcification (VC) is dramatically accelerated and is strongly associated with CVD events and mortality in HD patients. VC coexists with osteoporosis in many studies. Fibroblast growth factor 21 (FGF21) which is known as an adipocytokine is a new hypoglycemic strategy and is inversely related to bone mineral density. <b><i>Methods:</i></b> To evaluate the contribution of FGF21 to VC in HD patients, we detected circulating FGF21 levels and measured the whole thoracic aorta calcification scores (TACS) and calcification scores of the 3 segments of thoracic aorta, including ascending thoracic aorta (ATACS), aortic arch (AoACS), and descending thoracic aorta (DTACS) of our HD patients in this cross-sectional study. In addition, we pre-incubated human aortic endothelial cells (HAECs) with FGF21 in the presence or absence of parathyroid hormone (PTH) in vitro. <b><i>Results:</i></b> The median serum FGF21 level in HD patients was 11-fold higher than that in healthy controls. Ln(FGF21) was positively correlated with Ln(TACS+1), Ln(ATACS+1), Ln(AoACS+1), and Ln(DTACS+1), respectively, in HD patients. Serum FGF21 was independently associated with TACS and ATACS, AoACS, and DTACS. FGF21 which was combined with age, calcium, and intact PTH demonstrated a high area under the curve of 0.84 with optimal sensitivity (84%) and specificity (71%) for the prediction of VC in HD patients. Our vitro results showed that FGF21 enhanced the calcification effect of PTH on HAECs by increasing calcium deposition and endothelial-to-mesenchymal transition. <b><i>Conclusions:</i></b> Circulating FGF21 was notably higher and was a potential predictor and promoter of VC in HD patients.

Sign in / Sign up

Export Citation Format

Share Document